Shares of BioLife Solutions Inc (NASDAQ:BLFS) have been assigned an average recommendation of “Buy” from the eight brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $17.75.
A number of equities analysts recently weighed in on BLFS shares. ValuEngine raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Thursday, January 31st. BidaskClub lowered BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Wednesday, March 27th. Zacks Investment Research cut BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Tuesday, March 12th. Finally, Janney Montgomery Scott upgraded BioLife Solutions to a “buy” rating and set a $5.00 price objective on the stock in a report on Thursday, December 20th.
In related news, VP Todd Berard sold 3,000 shares of BioLife Solutions stock in a transaction on Tuesday, January 15th. The stock was sold at an average price of $12.12, for a total value of $36,360.00. Following the completion of the transaction, the vice president now directly owns 37,583 shares in the company, valued at $455,505.96. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Michael Rice sold 14,781 shares of BioLife Solutions stock in a transaction on Tuesday, January 15th. The shares were sold at an average price of $12.14, for a total value of $179,441.34. Following the completion of the transaction, the chief executive officer now owns 154,298 shares of the company’s stock, valued at $1,873,177.72. The disclosure for this sale can be found here. In the last three months, insiders sold 67,957 shares of company stock valued at $1,044,985. Insiders own 38.50% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. Roubaix Capital LLC purchased a new position in shares of BioLife Solutions in the 1st quarter valued at about $809,000. Vanguard Group Inc. lifted its stake in BioLife Solutions by 43.1% in the third quarter. Vanguard Group Inc. now owns 447,984 shares of the medical equipment provider’s stock worth $7,839,000 after acquiring an additional 134,869 shares during the last quarter. Vanguard Group Inc lifted its stake in BioLife Solutions by 43.1% in the third quarter. Vanguard Group Inc now owns 447,984 shares of the medical equipment provider’s stock worth $7,839,000 after acquiring an additional 134,869 shares during the last quarter. Sandler Capital Management grew its holdings in BioLife Solutions by 418.9% during the 3rd quarter. Sandler Capital Management now owns 783,820 shares of the medical equipment provider’s stock worth $13,717,000 after acquiring an additional 632,780 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in BioLife Solutions by 24.4% during the 2nd quarter. Northern Trust Corp now owns 16,304 shares of the medical equipment provider’s stock worth $186,000 after acquiring an additional 3,200 shares in the last quarter. 40.34% of the stock is currently owned by institutional investors.
Shares of NASDAQ BLFS traded down $0.10 during mid-day trading on Monday, reaching $17.56. 89,157 shares of the company’s stock were exchanged, compared to its average volume of 202,681. The stock has a market cap of $327.49 million, a PE ratio of 125.43 and a beta of 1.62. BioLife Solutions has a 52-week low of $6.59 and a 52-week high of $26.35.
BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, March 14th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.04. BioLife Solutions had a net margin of 16.54% and a return on equity of 11.15%. The firm had revenue of $5.46 million for the quarter, compared to analyst estimates of $5.47 million. Analysts expect that BioLife Solutions will post 0.13 EPS for the current fiscal year.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.
Featured Article: How is inflation measured?
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.